BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral
Record Year-to-Date Ending Q3 2026 Total New Debt and Equity Commitments of $3.44 Billion, an Increase of 20.0% Year-over-Year
Record Year-to-Date Ending Q3 2026 Total Fundings of $1.93 Billion, an Increase of 9.9%
The Total Cash Distribution of $0.47 per Share for the Third Quarter 2026 is Comprised of a $0.40 per Share Base Distribution and $0.07 per Share Supplemental Distribution
Hercules Capital, Inc. (NYSE:HTGC)
Fitch Additionally Affirms Secured Debt Rating at BBB
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage
Notes due 2029 Initially Assigned Ratings of Baa2 by Moody’s Investors Service and BBB- by Fitch Ratings, Inc.
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders,
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), today announced that it has priced an underwritten public offering of $400.0 million in aggregate principal
Multi-year growth-capital facility to fuel NorthStar’s commercial production scale-up of no-carrier-added Actinium-225 (n.c.a. Ac-225) to meet growing demand for next-generation targeted alpha therapies.
Capital
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage
New Equity Commitments Raised Across Two Institutional Private Credit Vehicles, Hercules Growth Lending IV and Hercules Evergreen Fund, Alongside a Rated Note Offering
Hercules Evergreen Fund is the Adviser’s
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hercules (HTGC) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage
Record 1H 2026 Total New Debt and Equity Commitments of $2.74 Billion, an Increase of 35.6% Year-over-Year
Record 1H 2026 Total Fundings of $1.35 Billion, an Increase of 8.5% Year-over-Year
Record 1H 2026 Total
The Total Cash Distribution of $0.47 per Share for the Second Quarter 2026 is Comprised of a $0.40 per Share Base Distribution and $0.07 per Share Supplemental Distribution
Hercules Capital, Inc. (NYSE:HTGC)
